{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:00:54Z","timestamp":1788458454493,"version":"build-2803163510"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Canadian HIV Cure Enterprise (CanCURE 2.0) Team","award":["HB2\u2013164064"],"award-info":[{"award-number":["HB2\u2013164064"]}]},{"DOI":"10.13039\/100008220","name":"Canadian Foundation for AIDS Research","doi-asserted-by":"publisher","award":["02\u2013512"],"award-info":[{"award-number":["02\u2013512"]}],"id":[{"id":"10.13039\/100008220","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vaccines & Immunotherapies Core of the CIHR Canadian HIV Trials Network","award":["CTN 247"],"award-info":[{"award-number":["CTN 247"]}]},{"name":"Fonds de la Recherche Qu\u00e9bec-Sant\u00e9 (FRQ-S): R\u00e9seau SIDA\/Maladies Infectieuses and Th\u00e9rapie cellulaire; the Canadian Institutes of Health Research","award":["PTJ 166049"],"award-info":[{"award-number":["PTJ 166049"]}]},{"name":"Fonds de la Recherche Qu\u00e9bec-Sant\u00e9 (FRQ-S): R\u00e9seau SIDA\/Maladies Infectieuses and Th\u00e9rapie cellulaire; the Canadian Institutes of Health Research","award":["HOP 103230"],"award-info":[{"award-number":["HOP 103230"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A 65-year-old woman successfully treated for human immunodeficiency virus (HIV) and Hepatitis C virus was diagnosed with porphyria cutanea tarda (PCT) and treated by phlebotomies. She developed extensive psoriatic skin lesions resistant to topical treatments and methotrexate. She then received the anti-interleukin-17 (IL-17) secukinumab (Cosentyx) which improved her psoriatic skin lesions. Unexpectedly, her PCT skin lesions healed, allowing phlebotomy discontinuation over 2 years. Without lesions, the patient decided to discontinue secukinumab, leading to the recurrence of psoriatic and PCT skin lesions, which were controlled upon therapeutical rechallenge. No AIDS-related manifestations or infections developed, her CD4 count remained elevated and her HIV viral load was controlled under antiretroviral therapy. Both skin conditions and consequently the patient\u2019s quality of life have improved with secukinumab, allowing exposure to sunlight and phlebotomy discontinuation for &amp;gt;4 years. Likely, the IL-17 pathway is involved in the clinical manifestations of PCT, opening new avenues for therapeutical interventions.<\/jats:p>","DOI":"10.1093\/omcr\/omad066","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T18:44:51Z","timestamp":1689878691000},"source":"Crossref","is-referenced-by-count":5,"title":["Control of porphyria cutanea tarda with anti-IL-17 secukinumab in a person with psoriasis living with HIV"],"prefix":"10.1093","volume":"2023","author":[{"given":"Helbies","family":"Bedier","sequence":"first","affiliation":[{"name":"McGill University Health Centre Department of Medicine, Division of Hematology, , Montreal, QC, Canada"},{"name":"Research Institute of the McGill University Health Centre Department of Infectious Diseases and Immunity in Global Health, , Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Isnard","sequence":"additional","affiliation":[{"name":"Research Institute of the McGill University Health Centre Department of Infectious Diseases and Immunity in Global Health, , Montreal, QC, Canada"},{"name":"McGill University Health Centre Department of Medicine, Chronic Viral Illness Service, , Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9jean","family":"Thomas","sequence":"additional","affiliation":[{"name":"Clinique l\u2019Actuel , Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9897-7589","authenticated-orcid":false,"given":"Jean-Pierre","family":"Routy","sequence":"additional","affiliation":[{"name":"McGill University Health Centre Department of Medicine, Division of Hematology, , Montreal, QC, Canada"},{"name":"Research Institute of the McGill University Health Centre Department of Infectious Diseases and Immunity in Global Health, , Montreal, QC, Canada"},{"name":"McGill University Health Centre Department of Medicine, Chronic Viral Illness Service, , Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"key":"2023072018422799200_ref1","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1056\/NEJMra1608634","article-title":"Porphyria","volume":"377","author":"Bissell","year":"2017","journal-title":"N Engl J Med"},{"key":"2023072018422799200_ref2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.gastro.2019.04.050","article-title":"Clinical guide and update on porphyrias","volume":"157","author":"Stolzel","year":"2019","journal-title":"Gastroenterology"},{"key":"2023072018422799200_ref3","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12090819","article-title":"Iron metabolism in the disorders of heme biosynthesis","volume":"12","author":"Ricci","year":"2022","journal-title":"Metabolites"},{"key":"2023072018422799200_ref4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"2023072018422799200_ref5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"2023072018422799200_ref6","doi-asserted-by":"crossref","DOI":"10.3390\/ph15111365","article-title":"A review of the safety of interleukin-17A inhibitor Secukinumab","volume":"15","author":"Eshwar","year":"2022","journal-title":"Pharmaceuticals"},{"key":"2023072018422799200_ref7","first-page":"60","article-title":"Cosentyx (Secukinumab): first IL-17A antagonist receives FDA approval for moderate-to-severe plaque psoriasis","volume":"9","author":"Fala","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"2023072018422799200_ref8","volume-title":"Cosentyx (Secukinumab) Injection [Prescribing Information]","author":"Novartis","year":"2016"},{"key":"2023072018422799200_ref9","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/cei.12899","article-title":"Systemic inflammation in acute intermittent porphyria: a case-control study","volume":"187","author":"Storjord","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"2023072018422799200_ref10","volume-title":"The Use of the WHO-UMC System for Standardised Case Causality Assessment","author":"W.H.O","year":"2013"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2023\/7\/omad066\/50901468\/omad066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2023\/7\/omad066\/50901468\/omad066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T18:45:11Z","timestamp":1689878711000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omad066\/7225612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omad066","relation":{},"ISSN":["2053-8855"],"issn-type":[{"value":"2053-8855","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7]]},"published":{"date-parts":[[2023,7,1]]},"article-number":"omad066"}}